Haemophilia A - Fixing the leak
Since factor VIII replacement therapies hit the market, life expectancy for haemophilia patients has risen to normal levels. But around 25% of those who suffer from haemophilia A still have no therapeutic options, because their immune systems form antibodies against clotting products that can stop bleeding. Researchers and companies in the growing US$15bn haemophilia medications market are feverishly exploring new ways to identify patients at risk and offer them alternative treatments, while a series of mergers and acquisitions have changed the playing field for established markets and players.
In this issue:
- Nanobots: Microscopic drug delivery systems – the next big thing
- Agrochemistry: Bayer-Monsanto to bet on genome editing in crop design
- Bioeconomy: Global policy leaders lay out agenda to push biologisation
- Biofairs Compass: The ultimate guide to leading Life Sciences Events in H2/2018
- Interview with Gallia Levy, Roche AG + Vas Narasimhan, Novartis AG + Rob Carlson, Bioeconomy Capital + Hannes Teissl, Polpharma Biologics + Federico Pollano, Rentschler Biopharma
- News from our partner associations Swiss Biotech Association, Medtec Europe and EuropaBio.